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ABSTRACT 
We examined the association between NSAID use and ovarian cancer by potential 
effect modifiers, parity and oral contraceptive use, in a population-based case-control 
study conducted in Wisconsin and Massachusetts. Women reported prior use of NSAIDs 
and information on risk factors in a telephone interview.  A total of 487 invasive ovarian 
cancer cases and 2653 control women aged 20-74 years were included in the analysis. 
After adjustment for age, state of residence and other covariates, ever use of NSAIDs was 
inversely associated with ovarian cancer in never users of oral contraceptives (odd ratio 
[OR]=0.58, 95% confidence interval [CI] 0.42-0.80) but not for ever users (OR=0.98, 
95% CI 0.71-1.35) (p-interaction=0.03). A reduced risk with NSAID use was also noted 
in nulliparous women (OR=0.47, 95% CI 0.27-0.82) but not among parous women 
(OR=0.81, 95% CI 0.64-1.04) (p-interaction=0.05).  These results suggest that use of 
NSAIDs were beneficial to women at greatest risk for ovarian cancer. 
 
KEY WORDS:  ovarian cancer, non-steroidal anti-inflammatory drugs, parity, oral 
contraceptives
 2
INTRODUCTION 
Over the last 10 years, a new hypothesis has emerged suggesting that the presence 
of chronic inflammation might play a causal role in the development of ovarian cancer 
(Ness & Cottreau, 1999).  Inflammation might be due to the process of ovulation itself or 
the presence of chronic inflammatory agents (Fleming et al, 2006).  Non-steroidal anti-
inflammatory drugs (NSAIDs) have been linked to a lower risk of several cancers 
(Bosetti et al, 2006), and NSAIDs could in theory have a similar protective influence in 
ovarian cancer by mitigating the deleterious effects of inflammation on ovarian 
epithelium.  Results of several observational studies and one randomized trial (Cook et 
al, 2005) of NSAIDs and ovarian cancer risk are inconsistent.  Five small studies detected 
a modestly decreased risk, but lacked statistical power (Akhmedkhanov et al, 2001; 
Cramer et al, 1998; Lacey et al, 2004; Rosenberg et al, 2000; Schildkraut et al, 2006).  
Five studies (Fairfield et al, 2002; Friis et al, 2003; Meier et al, 2002; Moysich et al, 
2001; Tavani et al, 2000) plus a meta-analysis (Bonovas et al, 2005) have demonstrated 
no association with aspirin or other non-aspirin NSAID use.  One study suggested an 
increased risk (Sorensen et al, 2003).  Lack of consistent findings in prior studies of 
NSAID use could reflect heterogeneity across study populations on factors such as parity 
and oral contraceptive use, which may reduce inflammation by suppressing ovulation.  
We explored the relationship of NSAID use with ovarian cancer risk, and whether 
NSAID associations depended on potential interactions with ovulatory factors in a US 
population-based case-control study.  
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 MATERIALS AND METHODS 
The study has been described in detail in previous reports (Peterson et al, 2006).  
Briefly, women aged 20-74 years diagnosed with incident invasive epithelial ovarian 
cancer (ICDO-C56) between 1998 and 2001 from Wisconsin and Massachusetts were 
identified through statewide cancer registries.  Controls were randomly selected in each 
state using two sampling frames: 1) for women <65 years, a list of licensed drivers; or 2) 
for women >65 years, rosters of Medicare beneficiaries compiled by the Centers for 
Medicare and Medicaid Services. All eligible controls had a publicly available telephone 
number.  Controls were frequency matched within 5-year stratum to the age distribution 
of ovarian and breast cancer cases enrolled in a concurrent study (Sprague et al, 2007).  
All study participants provided informed consent to participate.  Response rates were 
67% for cases and 82% for controls.   
All eligible women were mailed an introductory study letter prior to contact by 
study personnel.  A trained interviewer administered a 45-minute telephone survey which 
elicited information on use of NSAIDs, including the frequency, start and stop dates, 
duration of use, and type.  Only episodes of use prior to a reference date were included; 
the reference date was the date of diagnosis for cases and the date one year prior to 
interview for controls.  NSAIDs included both aspirin types and non-aspirin NSAID 
types (e.g., ibuprofen).  “Ever use” was defined as the use of any NSAID for at least 
twice per week for six months or more.  A woman was defined as a “current user” of 
NSAIDs if she reported use within 12 months of the reference date and lasting at least six 
months in duration.  “Former use” was defined as use for at least six months duration, but 
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prior to the 12 months preceding the reference date.  “Never use” was defined as use 
NSAIDs for less than 6 months or less than twice per week.  Information on other risk 
factors for ovarian cancer, including oral contraceptive use and parity, were also elicited 
during the interview.  Cases (n=18) and controls (n=562) were excluded if they had 
missing data on NSAID use. The final sample included 487 cases and 2653 controls. 
Multivariable logistic regression analysis was used to calculate odds ratios (OR) 
and 95 percent confidence intervals (CI) from Stata 9 (Stata Corp, College Station, TX) 
(Breslow & Day, 1980).  The main model included terms for age, state of residence, 
study year, menopausal status, body mass index, parity, oral contraceptive use, history of 
tubal ligation, hysterectomy, and family history of ovarian cancer. Tests for trend with 2-
sided p-values were evaluated by entering the categorical terms as an ordinal variable in 
the model.  To test for interaction of NSAIDs with oral contraceptive use and parity, a 
cross-product term was entered into the model, and the likelihood ratio test was used to 
test the difference between the full model and reduced model.   
 
RESULTS 
Case women were similar to control women with respect to age, education, age at 
first birth, and smoking status (Table 1).  Cases were more likely than control women to 
have not used oral contraceptives, be nulliparous or postmenopausal, have had a tubal 
ligation, or a family history of ovarian cancer.   
Overall, we observed a reduction in risk among women who had ever used any 
type of NSAID compared to non-users (OR=0.74, 95% CI 0.59-0.92) (data not shown). 
When considered according to oral contraceptive use, ever use of NSAIDs was inversely 
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associated with ovarian cancer in never users (OR=0.58, 95% CI=0.42-0.80) but there 
was no association among ever users (OR=0.98, 95% CI=0.71-1.35) of these medications 
(p-interaction=0.03) (Table 2). The reduction in risk was seen for both current and former 
users among never oral contraceptive users.  A reduced risk with NSAID use was limited 
to nulliparous women (OR=0.47, 95% CI=0.27-0.82) whereas there was little evidence of 
association among parous women (OR=0.81, 95% CI=0.64-1.04) (p-interaction=0.05).  
There was a significant decreasing trend in risk with increasing years of NSAID use 
among nulliparous women alone (p-trend=0.01).       
 
DISCUSSION 
Results from this study indicate an overall 30% reduction of ovarian cancer 
associated with ever and current use of  NSAIDs.  Further, NSAID users who are 
nulliparous or have not used oral contraceptives had the greatest reductions in risk.  Both 
pregnancy and use of oral contraceptives are associated with decreased ovarian cancer 
risk through their inhibitory effects on ovulation, due to incessant ovulation (Fathalla, 
1971).  At the site of ovum release, ovulation is associated with leukocyte invasion, 
release of nitric oxide and inflammatory cytokines, vasodilation, DNA repair, and tissue 
remodeling (Fleming et al, 2006).  The use of NSAIDs could potentially mitigate the 
inflammatory effect of ovulation, possibly at the site of ovarian inclusion cysts.  
There are some limitations which should be considered in the present analysis.  
We relied on the subject’s ability to recall use of NSAIDs, which could have introduced 
misclassification and potential bias towards the null.  While there are reports suggesting 
that age and education might influence recall, it has been shown that more-frequent use 
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of NSAIDs is more reliably recalled than less frequent use (Lewis et al, 2006)(West et al, 
1995).  Therefore, to improve the sensitivity, we attempted to identify true and consistent 
users by  limiting ever use of NSAIDs to at least two tablets per week for 6 months or 
more. 
These results suggest that NSAIDs may confer greater protection from ovarian 
cancer in women with higher background levels of inflammation from incessant 
ovulation.    
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TABLE 1.  Demographic characteristics of ovarian cancer cases and 
population-based controls. 
 Cases Controls 
 (n=487) (n=2,653) 
Demographic Characteristics N (%) N (%) 
Mean age (SD), years 55 (11.6) 54 (10.1) 
High school degree 196 (42.8) 1070 (42.8) 
Overweight or obese 272 (55.9) 1374 (51.8) 
Oral contraceptive use 220 (45.5) 1411 (53.7) 
Mean age (SD) at first birth, years 23.9 (4.5) 23.8 (4.5) 
Nulliparous 105 (21.6) 311 (11.7) 
Postmenopausal 309 (63.4) 1425 (53.7) 
Ever smoker 253 (52.0) 1402 (52.8) 
Tubal ligation 87 (17.9) 653 (24.6) 
Hysterectomy 107 (22.0) 380 (14.3) 
Family history of ovarian cancer 24 (4.9) 70 (2.6) 
 
 
 
 
 
 
 
 
 
 
   
TABLE 2.  Risk of ovarian cancer associated with NSAID use overall and stratified by oral contraceptive use and parity. 
        
        
               Cases Controls   Cases Controls     
NSAID use N (%)    N (%)    OR (95% CI)1 N (%)    N (%)    OR (95% CI)1,2 p-interaction 
 Overall   
Never use 336 (70.7)   1711 (65.7) 1.00 (Referent)     
Ever use 139 (29.3)   893 (34.3)  0.74 (0.59-0.92)     
  Former      45 ( 9.6)   220 ( 8.6)  0.96 (0.67-1.37)      
  Current 90 (19.1)   637 (24.8)  0.68 (0.52-0.88)     
        
Aspirin only 64 (16.0)  396 (18.8)  0.73 (0.54-1.00)     
Ibuprofen only 59 (14.9) 424 (19.9) 0.68 (0.50-0.93)     
        
Duration (years)        
  < 1 29 ( 6.1)   189 ( 7.3)  0.74 (0.49-1.14)     
  1-4 50 (10.5)   378 (14.5)  0.64 (0.46-0.88)     
  5-9 30 ( 6.3)   150 ( 5.8)  0.94 (0.61-1.44)      
  >10 30 ( 6.3)   176 ( 6.8)  0.78 (0.50-1.19)      
p-trend   0.03     
    
 Never used oral contraceptives Ever used oral contraceptives  
                (n=276)      (n=1483)    (n=222)     (n=1669)     
Never use 189 (74.1)   758 (63.7)  1.0 (Referent) 144 (66.4)  935 (67.4)  1.0 (Referent)  
Ever use 66 (25.9) 432 (36.3)  0.58 (0.42-0.80) 73 (33.6)   453 (32.6)  0.98 (0.71-1.35)  0.03 
  Former      18 ( 7.1) 94 ( 8.0)  0.69 (0.40-1.20) 27 (12.6)   125 ( 9.1)  1.32 (0.82-2.12)  0.1 
  Current 46 (18.2) 321 (27.4)  0.56 (0.39-0.80) 44 (20.5)   309 (22.6)  0.85 (0.58-1.26)   
        
Aspirin only 38 (15.0)   218 (18.4)  0.63 (0.42-0.93) 26 (12.0)   175 (12.7)  0.97 (0.60-1.57)  0.04 
Ibuprofen only 20 ( 7.9)   180 (15.2)  0.45 (0.27-0.75) 39 (18.1)   239 (17.3)  0.95 (0.63-1.43)   
        
Duration (years)        
  < 1 15 ( 5.9)   89 ( 7.5)  0.67 (0.37-1.21)  14 ( 6.5)   98 ( 7.1)  0.89 (0.48-1.65)  0.04 
  1-4 20 ( 7.8)   188 (15.8)  0.42 (0.26-0.69) 30 (13.8)   187 (13.5)  0.96 (0.61-1.49)   
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  5-9 14 ( 5.5)   76 ( 6.4)  0.62 (0.33-1.14)  16 ( 7.4)   72 ( 5.2)  1.56 (0.86-2.85)   
  >10 17 ( 6.7)   79 ( 6.6)  0.82 (0.46-1.45)  13 ( 6.0)   96 ( 6.9)  0.71 (0.36-1.39)   
p-trend   0.008   0.85  
        
 Nulliparous Parous  
                (n=110)      (n=382)    (n=392)     (n=2811)     
Never use 79 (78.2)   197 (64.4)  1.0 (Referent) 257 (68.7)  1514 (66.0)  1.0 (Referent)  
Ever use 22 (21.8)   109 (35.6)  0.47 (0.27-0.82) 117 (31.3)  781 (34.0)  0.81 (0.64-1.04)  0.05 
  Former      6 ( 6.0)   32 (10.6)  0.42 (0.16-1.08)  39 (10.5)   188 ( 8.3)  1.15 (0.78-1.68)  0.1 
  Current 15 (15.0)   72 (23.9)  0.48 (0.25-0.94) 75 (20.2)   562 (24.8)  0.72 (0.54-0.96)  
        
Aspirin only 8 ( 7.9)   40 (13.2)  0.48 (0.20-1.11) 56 (15.1)   355 (15.5)  0.78 (0.57-1.09)  0.3 
Ibuprofen only 12 (11.9)   60 (19.8)  0.45 (0.22-0.92) 47 (12.7)   362 (15.8)  0.77 (0.55-1.08)   
        
Duration (years)        
  < 1 7 ( 6.9)   20 ( 6.5)  0.80 (0.32-2.03)  22 ( 5.9)   167 ( 7.3)  0.75 (0.46-1.20)  0.03 
  1-4 6 ( 5.9)   51 (16.7)  0.30 (0.12-0.74) 44 (11.8)   326 (14.2)  0.72 (0.51-1.03)   
  5-9 4 ( 4.0)   17 ( 5.6)  0.54 (0.17-1.74)  26 ( 7.0)   133 ( 5.8)  1.06 (0.67-1.67)   
  >10 5 ( 5.0)   21 ( 6.9)  0.47 (0.15-1.48)  25 ( 6.7)   155 ( 6.8)  0.88 (0.55-1.39)   
p-trend     0.01     0.25  
1Adjusted for age, year of interview, state of residence, tubal ligation, family history of ovarian cancer, hysterectomy, and menopausal status. 
2Each analysis is adjusted for the other two variables in the table. 
 
